What is the Share Price of Balaxi Pharmaceuticals Ltd?
- Answer Field
-
The share price of Balaxi Pharmaceuticals Ltd for NSE is ₹ 55.4 and for BSE is ₹ 0.00.
BAJAJ BROKING
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
As of the latest trading session, BALAXI PHARMA LTD share price is currently at ₹ 55.4, which is down by ₹ -1.55 from its previous closing. Today, the stock has fluctuated between ₹ 55.00 and ₹ 57.08. Over the past year, BALAXI PHARMA LTD has achieved a return of -54.89 %. In the last month alone, the return has been -17.65 %. Read More...
Particulars | DEC 2024 (Values in Cr) |
---|---|
Revenue | 11.16 |
Operating Expense | 11.74 |
Net Profit | 1.74 |
Net Profit Margin (%) | 15.59 |
Earnings Per Share (EPS) | 0.32 |
EBITDA | 3.01 |
Effective Tax Rate (%) | 25.32 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.46 | 19.60 | 1.99 | 279.41 | 34.11 / 77.70 |
BLISS GVS PHARMA LTD | 119.00 | 15.60 | 1.24 | 1253.91 | 92.25 / 184.95 |
CIPLA LTD | 1549.65 | 25.08 | 4.41 | 125155.99 | 1310.05 / 1702.00 |
FERMENTA BIOTECH LIMITED | 260.70 | 21.60 | 2.64 | 767.27 | 145.00 / 449.00 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.46 | 21.96 | 6.19 | 279.41 | 34.11 / 77.70 |
AMRUTAJAN HEALTH LTD | 692.80 | 40.61 | 6.72 | 2002.93 | 548.05 / 861.40 |
ASTRAZENECA PHARMA IND LT | 8665.50 | 129.24 | 31.88 | 21663.75 | 5000.00 / 9199.00 |
BLISS GVS PHARMA LTD | 119.00 | 15.45 | 1.22 | 1253.91 | 92.25 / 184.95 |
Balaxi Pharmaceuticals has shown a mixed performance for the quarter ending June 2024. Despite a slight decline in net sales, which dipped by 0.51% year-over-year to Rs 65.62 crore, the company achieved a significant increase in net profit. The net profit soared by 115.67%, reaching Rs 6.48 crore compared to Rs 3.01 crore in the same period last year. Read More... The EBITDA also saw a modest rise of 5.1%, standing at Rs 8.24 crore. This strong profitability, despite flat sales, may positively influence the Balaxi Pharma share price. Investors are likely to view this as a sign of improved operational efficiency and profitability, which could drive future growth. Read Less
The annual report of Balaxi Pharmaceuticals offers a detailed overview of the company's financial and operational performance over the past fiscal year. It provides insights into revenue streams, cost management, and profitability, which are crucial for understanding the company's overall health and growth prospects. For those tracking the Balaxi Pharma share price, Read More...the annual report is an essential document that sheds light on the company's strategic direction, market positioning, and potential for future growth. It also includes information on the company’s governance practices and sustainability initiatives, providing a comprehensive picture of its operations. Read Less
Balaxi Pharmaceuticals' dividend policy is a key point of interest for investors, particularly given the company's strong net profit growth in the recent quarter. While net sales remained relatively flat, the significant increase in profitability could result in favorable dividend payouts. The Balaxi Pharma share price could be positively impacted by a strong dividend announcement, signaling the company’s commitment to returning value to its shareholders. Investors will be looking closely at the upcoming dividend declaration to gauge the company’s financial stability and its approach to balancing growth with shareholder returns.
Balaxi Ventures Limited was formerly incorporated in the name of 'The Anandam Rubber Company Limited' on September 28, 1942. The Company changed its name from 'The Anandam Rubber Company Limited' to 'Balaxi Ventures Limited' on August 08, 2017. The Company incorporated with a basic objective of running rubber and tea plantations and owns several plantations across South India.
In year 1989 the company sold its entire plantations to meet the emerging business needs and started concentrating in Investments and trading. The company previously was a investment company, but the company during the financial year 2018-19 has commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG Products
On 15 March 2017, Balaxi Overseas Private Limited (BOPL) entered into a Share Purchase Agreement (SPA) with the erstwhile promoters of Company (i.e. Mr. Nirej V. Paul, Mr. V. M. Paulose, Dr. Leelamma T. J and Mrs. Jaya Paul) to acquire 1,670,036 Equity Shares representing 54.94% of the paid up share capital of the Company along with the control over the Company, pursuant to which BOPL made an Open Offer under Regulation 3(1) and Regulation 4 of SEBI (SAST) Regulations, 2011. Control and management of the Company was acquired by BOPL on May 04, 2017 and it became the new promoter of Company and their representatives i.e. Mr. Ashish Maheshwari and Mrs. Minoshi Maheshwari became the new Directors of the Company. Simultaneously, erstwhile promoters stepped down as promoters from Company on same day and Mr. Nirej V. Paul and Dr. Leelamma TJ resigned as Managing Director and as Chairperson from the Company, respectively. Under the above said Open Offer, BOPL acquired 3,30,000 equity shares representing 10.86% equity share capital of the Company. On completion of the Open Offer BOPL became the holding and Promoter Company with an aggregate shareholding of 2000036 Equity Shares (ie 65.79%).
The main objects of the company were amended to include activities of International wholesale trading in pharmaceutical, food products and builders' hardware on August 08, 2018. The Company commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG products from Financial Year 2018-19.
Further, in February 2019, it kickstarted Food Products business by launching a range of biscuits under the brand YAP'.
The Company expanded its presence by establishing a central distribution warehouse in Guatemala, marking its entry into the third geography. This expansion helped in strengthening the distribution network and a wider customer base in 2019.
In FY 2023, Company started operations in two Latin American Countries, i.e., Honduras and El Salvador and also started operations in
the Central African Republic.
The share price of Balaxi Pharmaceuticals Ltd for NSE is ₹ 55.4 and for BSE is ₹ 0.00.
The market cap of Balaxi Pharmaceuticals Ltd for NSE is ₹ 60.37 Cr. and for BSE is ₹ 0.0 Cr. as of now.
The 52 Week High and Low of Balaxi Pharmaceuticals Ltd for NSE is ₹ 151.45 and ₹ 50.42 and for BSE is ₹ 0.00 and ₹ 0.00.
You can trade in Balaxi Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.
The 1 year returns on the stock has been -54.89%.
Balaxi Pharmaceuticals Ltd share price is for NSE ₹ 55.4 & for BSE ₹ 0.00 as on Apr 30 2025 03:29 PM.
The market cap of Balaxi Pharmaceuticals Ltd for NSE ₹ 60.37 & for BSE ₹ 0.0 as on Apr 30 2025 03:29 PM.
As on Apr 30 2025 03:29 PM the price-to-earnings (PE) ratio for Balaxi Pharmaceuticals Ltd share is 72.58.
As on Apr 30 2025 03:29 PM, the price-to-book (PB) ratio for Balaxi Pharmaceuticals Ltd share is 23.05.
You can trade in Balaxi Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.
To buy Balaxi Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Balaxi Pharmaceuticals Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found